William Blair analyst Myles Minter has reiterated their bullish stance on ARCT stock, giving a Buy rating on March 10.
Myles Minter has given his Buy rating due to a combination of factors that highlight the potential growth and strategic positioning of Arcturus Therapeutics. The company is poised to benefit from upcoming Phase II trial data for its ARCT-032 and ARCT-810 treatments, which target cystic fibrosis and ornithine transcarbamylase deficiency, respectively. These trials are expected to provide significant insights by the end of the second quarter of 2025, and positive outcomes could enhance the company’s market position.
Minter also notes the strategic financial adjustments Arcturus is making, such as delaying the recognition of Kostaive profit share revenues until the fourth quarter of 2026. This decision is aligned with covering a 40% cost share with CSL, which is expected to stabilize the company’s financials in the long term. Additionally, while collaborative revenue projections for 2025 have been reduced, the potential for milestone payments upon EU approval and future U.S. regulatory filings presents a promising outlook for revenue growth beyond 2025.
In another report released on March 10, Canaccord Genuity also maintained a Buy rating on the stock with a $68.00 price target.
Questions or Comments about the article? Write to editor@tipranks.com